National Heart, Lung, and Blood Institute Proteomics Initiative

项目目标 招标编号：NHLBI-HL-02-04 C合同编号：N 01-HV-28184 供应商名称和地址： 德克萨斯大学医学分支加尔维斯顿 大学大道301号 加尔维斯顿，德克萨斯州77555-0657 RFP标题：国家心脏、肺和血液研究所蛋白质组学倡议 主要负责人：亚历山大库罗斯基博士 研究气道炎症的蛋白质组学技术 证据摘要： 一个全面的和创新的蛋白质组学战略将开发一个模型的研究方法，使用新的技术通常适用于许多NHLBI的研究兴趣。具体来说，我们将采用蛋白质组学为基础的技术，以调查蛋白质的表达与信号通路的重要炎症条件的气道。具体目标是：1）开发灵敏的高分辨率蛋白质分离技术，以构建炎症气道主要细胞类型中细胞和亚细胞蛋白质表达变化的蛋白质数据库; 2）开发创新的基于硫代适体的阵列和珠技术，以鉴定和定量与气道炎症相关的关键信号传导和免疫应答途径相关的蛋白质和蛋白质复合物; 3）利用专门的高通量流式细胞术/细胞分选，用于细胞选择的激光冲击/成像的新技术，磁激活细胞分选，以及激光捕获显微切割，用于细胞周期特定阶段中定义的细胞类型的后续蛋白质组分析;以及4）应用系统建模以将蛋白质表达的变化与关于由于呼吸道合胞病毒感染或哮喘后的炎症引起的基因表达变化的可用基因组数据相关联。

PROJECT OBJECTIVES SOLICITATION NUMBER: NHLBI-HL-02-04 C ONTRACT NUMBER: N01-HV-28184 OFFEROR NAME AND ADDRESS: The University of Texas Medical Branch at Galveston 301 University Boulevard Galveston, Texas 77555-0657 RFP TITLE: National Heart, Lung, and Blood Institute Proteomics Initiative PRINCIPAL INVESTIGATOR: Dr. Alexander Kurosky Proteomic Technologies to Study Airway Inflammation SUMMARY OF OBJECTIVES: A comprehensive and innovative proteomics strategy will develop a model investigative approach using novel technologies generally applicable to many NHLBI research interests. Specifically, we will employ proteomics-based technologies to investigate protein expression associated with signaling pathways important in inflammatory conditions of the airways. Specific aims are to: 1) Develop sensitive high-resolution protein separation technologies to construct protein databases of changes in cellular and subcellular protein expression in the major cell types of inflamed airways; 2) Develop innovative thioaptamer-based array and bead technologies to identify and quantify proteins and protein complexes associated with critical signaling and immune response pathways relating to airway inflammation; 3) Utilize specialized high-throughput flow cytometry/cell sorting, new technology for laser zapping/imaging for cell selection, magnetic-activated cell sorting, and laser-capture microdissection for subsequent proteome analysis of defined cell types in specific stages of the cell cycle; and 4) Apply systems modeling to correlate changes in protein expression with available genomic data on changes in gene expression due to inflammation after respiratory syncytial virus infection or asthma.